"Chemokine CXCL5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A CXC chemokine that is predominantly expressed in EPITHELIAL CELLS. It has specificity for the CXCR2 RECEPTORS and is involved in the recruitment and activation of NEUTROPHILS.
| Descriptor ID |
D054365
|
| MeSH Number(s) |
D12.644.276.374.200.120.250 D12.776.467.374.200.120.250 D23.125.300.120.250 D23.469.200.120.250 D23.529.374.200.120.250
|
| Concept/Terms |
Chemokine CXCL5- Chemokine CXCL5
- CXCL5, Chemokine
- Epithelial-Cell-Derived Neutrophil Attractant-78
- Epithelial Cell Derived Neutrophil Attractant 78
- Neutrophil Attractant-78, Epithelial-Cell-Derived
- ENA-78 Chemokine
- ENA 78 Chemokine
- Endothelial Neutrophil-Activating Peptide 78
- Endothelial Neutrophil Activating Peptide 78
- Chemokine (C-X-C Motif) Ligand 5 Protein
- CXCL5 Chemokine
- Chemokine, CXCL5
|
Below are MeSH descriptors whose meaning is more general than "Chemokine CXCL5".
Below are MeSH descriptors whose meaning is more specific than "Chemokine CXCL5".
This graph shows the total number of publications written about "Chemokine CXCL5" by people in this website by year, and whether "Chemokine CXCL5" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Chemokine CXCL5" by people in Profiles.
-
A C-X-C Chemokine Receptor Type 2-Dominated Cross-talk between Tumor Cells and Macrophages Drives Gastric Cancer Metastasis. Clin Cancer Res. 2019 06 01; 25(11):3317-3328.
-
Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokines. Microb Pathog. 2018 Aug; 121:9-21.